Search - tctmd.com

Displaying 1 - 20 of 167

Sort: Relevancy | Date

News Daily News

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

Caitlin E. Cox

November 24, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Todd Neale

December 06, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Conference News ESC 2024

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

Michael O'Riordan

September 01, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI

Michael O'Riordan

March 26, 2024

News Daily News

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

Todd Neale

March 04, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest

Michael O'Riordan

January 30, 2024

News Daily News

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Michael O'Riordan

January 09, 2024

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

Advertisement

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content